A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
ConditionNon-Small-Cell Lung
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAstraZeneca
About this trial
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
Eligibility criteria
Qualifiers
Stage I-III at initial NSCLC diagnosis
Aged ≥18 years at first diagnosis of NSCLC
Disqualifiers
NSCLC is not the primary cancer diagnosis
Patients with a recent history of other tumor or concurrent other tumor
Patients participating in interventional clinical trials at time of initial diagnosis
Patients with positive pregnancy status at the time of diagnosis
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
1Research Site Beijing China
Sponsors and collaborators
AstraZeneca
Lead sponsor
Source ClinicalTrials.gov